Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well cilengitide works in treating patients
with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma
by stopping blood flow to the tumor.